DISC-3405

Phase 2Small molecule

DDisc Medicine, Inc

DISC-3405 is one of 76 small molecule programs targeting Polycythemia Vera. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Adakveo

Novartis

Phase 3

7 2

Exjade

Novartis

Phase 3

4 3

Brilinta

AstraZeneca

Phase 3

3 4

Ritalin

Novartis

Phase 3

2 5

Cysteine Hydrochloride

Novartis

Phase 3

2 6

Eliquis

Bristol-Myers Squibb

Phase 3

1 7

Oxbryta

GGlobal Blood Therapeutics

Phase 3

5 8

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 9

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

3 10

Xarelto

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Sickle Cell Disease

NCT07187973

Q1 2029

Phase 2Recruiting

Polycythemia Vera

NCT06985147

Clinical

Trials by Indication[1]

Polycythemia Vera1 trial

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Recruiting·DDisc Medicine, Inc·Phase 2·NCT06985147·60 enrolled

Sickle Cell Disease1 trial

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Recruiting·DDisc Medicine, Inc·Phase 1·NCT07187973·24 enrolled

Unspecified1 trial

A Study of DISC-3405 in Healthy Volunteers

Completed·DDisc Medicine, Inc·Phase 1·NCT06050915·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DISC-3405. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DISC-3405 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DISC-3405. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Disc Medicine, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDisc Medicine, Inc

DISC-3405

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2029

Trials by Indication[1]

Polycythemia Vera1 trial

Sickle Cell Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News